Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial

Tito Livraghi, Franca Meloni, Alberto Frosi, Sergio Lazzaroni, Mariano Bizzarri, Luigi Frati, Pier Mario Biava

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

There is no standard treatment for patients with advanced hepatocellular carcinoma (HCC). We developed a product containing stem cells differentiation stage factors (SCDSF) that inhibits tumor growth in vivo and in vitro. The aim of this open randomized study was to assess its efficacy in patients with HCC not suitable for resection, transplantation, ablation therapy, or arterial chemoembolization. A total of 179 consecutive patients were enrolled. We randomly assigned the patients to receive either SCDSF or only conservative treatment. Primary end points were tumor response and survival. Secondary end points were performance status and patient tolerance. Randomization was stopped at the second interim analysis (6 months) of the first 32 patients recruited when the inspection detected a significant difference in favor of treatment (p = 0.037). The responses to the therapy obtained in 154 additional patients confirmed previous results. Evaluation of survival showed a significant difference between the group of patients who responded to treatment versus the group with progression of disease (p <0.001). Of the 23 treated patients with a performance status (PS) of 1, 19 changed to 0. The study indicated the efficacy of SCDSF treatment of the patients with intermediate-advanced HCC.

Original languageEnglish
Pages (from-to)399-408
Number of pages10
JournalOncology Research
Volume15
Issue number7-8
Publication statusPublished - 2005

Fingerprint

Cell Differentiation
Hepatocellular Carcinoma
Stem Cells
Randomized Controlled Trials
Therapeutics
Survival
Random Allocation
Disease Progression
Neoplasms
Transplantation
Growth

Keywords

  • Biological response modifiers
  • Differentiation factors
  • Embryo
  • Hepatocellular carcinoma
  • Stem cells

ASJC Scopus subject areas

  • Cancer Research

Cite this

Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma : An open randomized clinical trial. / Livraghi, Tito; Meloni, Franca; Frosi, Alberto; Lazzaroni, Sergio; Bizzarri, Mariano; Frati, Luigi; Biava, Pier Mario.

In: Oncology Research, Vol. 15, No. 7-8, 2005, p. 399-408.

Research output: Contribution to journalArticle

Livraghi, T, Meloni, F, Frosi, A, Lazzaroni, S, Bizzarri, M, Frati, L & Biava, PM 2005, 'Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial', Oncology Research, vol. 15, no. 7-8, pp. 399-408.
Livraghi, Tito ; Meloni, Franca ; Frosi, Alberto ; Lazzaroni, Sergio ; Bizzarri, Mariano ; Frati, Luigi ; Biava, Pier Mario. / Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma : An open randomized clinical trial. In: Oncology Research. 2005 ; Vol. 15, No. 7-8. pp. 399-408.
@article{3685e0810f5341a28896417665223c32,
title = "Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: An open randomized clinical trial",
abstract = "There is no standard treatment for patients with advanced hepatocellular carcinoma (HCC). We developed a product containing stem cells differentiation stage factors (SCDSF) that inhibits tumor growth in vivo and in vitro. The aim of this open randomized study was to assess its efficacy in patients with HCC not suitable for resection, transplantation, ablation therapy, or arterial chemoembolization. A total of 179 consecutive patients were enrolled. We randomly assigned the patients to receive either SCDSF or only conservative treatment. Primary end points were tumor response and survival. Secondary end points were performance status and patient tolerance. Randomization was stopped at the second interim analysis (6 months) of the first 32 patients recruited when the inspection detected a significant difference in favor of treatment (p = 0.037). The responses to the therapy obtained in 154 additional patients confirmed previous results. Evaluation of survival showed a significant difference between the group of patients who responded to treatment versus the group with progression of disease (p <0.001). Of the 23 treated patients with a performance status (PS) of 1, 19 changed to 0. The study indicated the efficacy of SCDSF treatment of the patients with intermediate-advanced HCC.",
keywords = "Biological response modifiers, Differentiation factors, Embryo, Hepatocellular carcinoma, Stem cells",
author = "Tito Livraghi and Franca Meloni and Alberto Frosi and Sergio Lazzaroni and Mariano Bizzarri and Luigi Frati and Biava, {Pier Mario}",
year = "2005",
language = "English",
volume = "15",
pages = "399--408",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "7-8",

}

TY - JOUR

T1 - Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma

T2 - An open randomized clinical trial

AU - Livraghi, Tito

AU - Meloni, Franca

AU - Frosi, Alberto

AU - Lazzaroni, Sergio

AU - Bizzarri, Mariano

AU - Frati, Luigi

AU - Biava, Pier Mario

PY - 2005

Y1 - 2005

N2 - There is no standard treatment for patients with advanced hepatocellular carcinoma (HCC). We developed a product containing stem cells differentiation stage factors (SCDSF) that inhibits tumor growth in vivo and in vitro. The aim of this open randomized study was to assess its efficacy in patients with HCC not suitable for resection, transplantation, ablation therapy, or arterial chemoembolization. A total of 179 consecutive patients were enrolled. We randomly assigned the patients to receive either SCDSF or only conservative treatment. Primary end points were tumor response and survival. Secondary end points were performance status and patient tolerance. Randomization was stopped at the second interim analysis (6 months) of the first 32 patients recruited when the inspection detected a significant difference in favor of treatment (p = 0.037). The responses to the therapy obtained in 154 additional patients confirmed previous results. Evaluation of survival showed a significant difference between the group of patients who responded to treatment versus the group with progression of disease (p <0.001). Of the 23 treated patients with a performance status (PS) of 1, 19 changed to 0. The study indicated the efficacy of SCDSF treatment of the patients with intermediate-advanced HCC.

AB - There is no standard treatment for patients with advanced hepatocellular carcinoma (HCC). We developed a product containing stem cells differentiation stage factors (SCDSF) that inhibits tumor growth in vivo and in vitro. The aim of this open randomized study was to assess its efficacy in patients with HCC not suitable for resection, transplantation, ablation therapy, or arterial chemoembolization. A total of 179 consecutive patients were enrolled. We randomly assigned the patients to receive either SCDSF or only conservative treatment. Primary end points were tumor response and survival. Secondary end points were performance status and patient tolerance. Randomization was stopped at the second interim analysis (6 months) of the first 32 patients recruited when the inspection detected a significant difference in favor of treatment (p = 0.037). The responses to the therapy obtained in 154 additional patients confirmed previous results. Evaluation of survival showed a significant difference between the group of patients who responded to treatment versus the group with progression of disease (p <0.001). Of the 23 treated patients with a performance status (PS) of 1, 19 changed to 0. The study indicated the efficacy of SCDSF treatment of the patients with intermediate-advanced HCC.

KW - Biological response modifiers

KW - Differentiation factors

KW - Embryo

KW - Hepatocellular carcinoma

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=32044471340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044471340&partnerID=8YFLogxK

M3 - Article

C2 - 16491958

AN - SCOPUS:32044471340

VL - 15

SP - 399

EP - 408

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 7-8

ER -